International Ophthalmology

, Volume 33, Issue 2, pp 177–180 | Cite as

Central serous chorioretinopathy due to tadalafil use

  • Fatih Mehmet Türkcü
  • Harun Yüksel
  • Alparslan Şahin
  • Mehmet Murat
  • Yaşar Bozkurt
  • İhsan Çaça
Case Report


Phosphodiesterase-5 (PDE5) inhibitors are commonly used in the treatment of erectile dysfunction. There are a small number of case reports that associate this agent with central serous chorioretinopathy (CSCR). Our report presents the treatment approach to a 42-year-old patient who described blurred vision and metamorphopsia and was diagnosed with CSCR following the use of tadalafil, a PDE5 inhibitor.


Central serous chorioretinopathy Phosphodiesterase-5 Tadalafil 


  1. 1.
    Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S (2004) Central serous chorioretinopathy case-control study group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249PubMedCrossRefGoogle Scholar
  2. 2.
    Scheider A, Nasemann JE, Lund OE (1993) Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser opthalmoscopy. Am J Ophthalmol 115:50–65PubMedGoogle Scholar
  3. 3.
    Prunte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121:26–34PubMedGoogle Scholar
  4. 4.
    Iida T, Kishi S, Hagimura N, Shimizu K (1999) Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 19:508–512PubMedCrossRefGoogle Scholar
  5. 5.
    Melman A, Gingell JC (1999) The epidemiology and pathophysiology of erectile dysfunction. J Urol 161:5–11PubMedCrossRefGoogle Scholar
  6. 6.
    Lue TF (1990) Impotence: a patient goal directed approach to treatment. World J Urol 8:67–74CrossRefGoogle Scholar
  7. 7.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction sildenafil study group. N Engl J Med 338:1397–1404PubMedCrossRefGoogle Scholar
  8. 8.
    Lugnier C (2006) Cylic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366–398PubMedCrossRefGoogle Scholar
  9. 9.
    Laties AM, Zrenner E (2002) Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 21:485–500PubMedCrossRefGoogle Scholar
  10. 10.
    Carter JE (2007) Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause and coincidence? J Neurol Sci 262:89–97PubMedCrossRefGoogle Scholar
  11. 11.
    Foresta C, Caretta N, Zuccarello D, Poletti A, Biagioli A, Caretti L (2008) Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. Eye 22:144–149PubMedCrossRefGoogle Scholar
  12. 12.
    Quiram P, Dumars S, Parwar B, Sarraf D (2005) Viagra-associated serous macular detachment. Graefes Arch Clin Exp Ophthalmol 243:339–344PubMedCrossRefGoogle Scholar
  13. 13.
    French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274PubMedCrossRefGoogle Scholar
  14. 14.
    Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB (2012) Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 227:85–89PubMedCrossRefGoogle Scholar
  15. 15.
    Gordon-Bennett P, Rimmer T (2012) Central serous chorioretinopathy following oral tadalafil. Eye 26:168–169PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Fatih Mehmet Türkcü
    • 1
  • Harun Yüksel
    • 1
  • Alparslan Şahin
    • 1
  • Mehmet Murat
    • 1
  • Yaşar Bozkurt
    • 2
  • İhsan Çaça
    • 1
  1. 1.Department of OphthalmologyFaculty of Medicine, Dicle UniversityDiyarbakirTurkey
  2. 2.Department of UrologyFaculty of Medicine, Dicle UniversityDiyarbakirTurkey

Personalised recommendations